Oxler Private Wealth LLC Sells 142 Shares of Abbott Laboratories (NYSE:ABT)

Oxler Private Wealth LLC reduced its holdings in Abbott Laboratories (NYSE:ABT) by 0.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,783 shares of the healthcare product maker’s stock after selling 142 shares during the quarter. Oxler Private Wealth LLC’s holdings in Abbott Laboratories were worth $2,011,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Central Pacific Bank Trust Division grew its position in Abbott Laboratories by 2.3% in the third quarter. Central Pacific Bank Trust Division now owns 4,045 shares of the healthcare product maker’s stock worth $461,000 after acquiring an additional 91 shares in the last quarter. Czech National Bank boosted its holdings in shares of Abbott Laboratories by 6.9% in the 3rd quarter. Czech National Bank now owns 354,435 shares of the healthcare product maker’s stock worth $40,409,000 after purchasing an additional 22,932 shares in the last quarter. Farmers Trust Co. increased its position in shares of Abbott Laboratories by 0.9% during the 3rd quarter. Farmers Trust Co. now owns 24,781 shares of the healthcare product maker’s stock valued at $2,825,000 after purchasing an additional 230 shares during the last quarter. Canandaigua National Bank & Trust Co. raised its holdings in shares of Abbott Laboratories by 5.3% during the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 66,470 shares of the healthcare product maker’s stock valued at $7,578,000 after buying an additional 3,330 shares in the last quarter. Finally, Apella Capital LLC lifted its position in Abbott Laboratories by 3.1% in the 3rd quarter. Apella Capital LLC now owns 6,191 shares of the healthcare product maker’s stock worth $704,000 after buying an additional 185 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. UBS Group lifted their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Barclays reissued an “overweight” rating and issued a $158.00 price target (up from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Evercore ISI lifted their price objective on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. Raymond James restated a “buy” rating and set a $129.00 target price (up from $122.00) on shares of Abbott Laboratories in a report on Monday, October 14th. Finally, Piper Sandler boosted their price objective on Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $133.06.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.10% of the company’s stock.

Abbott Laboratories Stock Down 0.9 %

Shares of NYSE ABT opened at $127.69 on Friday. The firm has a fifty day simple moving average of $116.17 and a two-hundred day simple moving average of $114.00. The firm has a market capitalization of $221.47 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 2.38 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $129.85.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same period last year, the business posted $1.19 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.2% compared to the same quarter last year. Equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $0.59 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.85%. Abbott Laboratories’s dividend payout ratio is 30.85%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.